



RECEIVED  
CENTRAL FAX CENTER  
NOV 10 2011

ATTORNEYS AT LAW  
WASHINGTON HARBOUR  
3000 K STREET, N.W.  
SUITE 600  
WASHINGTON, D.C. 20007-5109  
202.672.5300  
202.672.5399  
WWW.FOLEY.COM

sbent@foley.com  
202.672.5404

## MEMORANDUM

CLIENT-MATTER NUMBER  
060348-0149

**TO:** Anoop Kumar Singh,  
Examiner U.S. Patent and Trademark Office  
Art Unit 1632

**FROM:** Stephen A. Bent, Foley & Lardner LLP  
Reg. No. 29786

**DATE:** November 10, 2011

**RE:** *Request for Teleconference on Proposal for  
Claim Revisions in U.S. SN 10/588028*

Dear Dr. Singh,

Would you be willing to receive my call, at your convenience, to discuss a proposed revision, illustrated below, to the main claim of the captioned application?

If so, please let me know when and where I can reach you for this purpose.

Thanks for your attention to this request.

SAB

\*\*\*\*\*

### 8. A targeted drug delivery method that comprises

- (A) providing a composition comprising (i) intact, bacterially derived minicells that are approximately 400 nm in diameter and that are loaded with a therapeutically significant concentration of a small molecule drug chemotherapeutic agent and (ii) bispecific ligands having specificity for a mammalian cell surface receptor and specificity for said minicells, wherein said composition is free of membrane blebs of 200 nm or less in size; and
- (B) contacting said composition with non-phagocytic mammalian cells, such that (i) said bispecific ligands cause said minicells to bind to said mammalian cells, (ii) said minicells are engulfed by said mammalian cells, and (iii) said small molecule drug chemotherapeutic agent is released into the cytoplasm of said mammalian cells.

4834-7689-0893.1